VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission
source: pixabay.com

VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission

As reported in Business Wire; VerSIM Life, a company that uses computational sciences to create novel machine learning to aid drug development, has announced that they are launching a pharmaceutical…

Continue Reading VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission
There’s a New Molecular Target for IPF, Research Shows
Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

There’s a New Molecular Target for IPF, Research Shows

An estimated 13-20 out of every 100,000 people around the globe have idiopathic pulmonary fibrosis (IPF). The condition often has a poor prognosis (3-5 years following diagnosis) and there are…

Continue Reading There’s a New Molecular Target for IPF, Research Shows

Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis

Growth differentiation factor 15 (GDF15) is expressed in normal conditions but is overly expressed when cells are under stress. It has multiple roles in different diseases and has been used…

Continue Reading Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis
Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising
source: pixabay.com

Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising

According to a story from GlobeNewswire, the biotechnology company Galecto, Inc., has recently published the results from its phase 2a clinical trial. This study was testing the company's experimental therapy…

Continue Reading Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising
Presentation: Tyvaso as a Treatment for Interstitial Lung Disease
source: pixabay.com

Presentation: Tyvaso as a Treatment for Interstitial Lung Disease

United Therapeutics Corporation has recently presented data from the Phase 3 INCREASE trial, which evaluated Tyvaso as a treatment for pulmonary hypertension associated with interstitial lung disease. Results were presented…

Continue Reading Presentation: Tyvaso as a Treatment for Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis Treatment Does Well In Preclinical Trial
source: pixabay.com

Idiopathic Pulmonary Fibrosis Treatment Does Well In Preclinical Trial

Cynata Therapeutics Limited has recently announced the results from their preclinical trial of induced pluripotent stem cell (iPSC)-derived Cymerus™ mesenchymal stem cells (MSCs), according to BioSpace. They are testing these…

Continue Reading Idiopathic Pulmonary Fibrosis Treatment Does Well In Preclinical Trial
September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness

According to a story from Newswise, September is recognized as Pulmonary Fibrosis Awareness Month. This includes idiopathic pulmonary fibrosis (IPF), or disease without an identifiable cause. In the midst of…

Continue Reading September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness

Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease

A team of researchers recently evaluated a new biomarker in interstitial lung disease to see whether or not it could predict disease severity and ultimately mortality. The Biomarker Surfactant protein…

Continue Reading Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease
First Ever Test Which can Predict Progression in Idiopathic Pulmonary Fibrosis is Making Progress
source: pixabay.com

First Ever Test Which can Predict Progression in Idiopathic Pulmonary Fibrosis is Making Progress

Idiopathic Pulmonary Fibrosis Progression Veracyte has just signed a deal with Yale University which will help them develop the very first test which can predict disease progression for idiopathic pulmonary…

Continue Reading First Ever Test Which can Predict Progression in Idiopathic Pulmonary Fibrosis is Making Progress
New Genetic Test Can Predict Disease Progression of Idiopathic Pulmonary Fibrosis
Source: Pixabay

New Genetic Test Can Predict Disease Progression of Idiopathic Pulmonary Fibrosis

Predicting the disease progression of idiopathic pulmonary fibrosis (IPF) is extremely important, as this condition progresses differently depending on the affected individual. Knowing if one has a poor outcome while…

Continue Reading New Genetic Test Can Predict Disease Progression of Idiopathic Pulmonary Fibrosis
A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
source: pixabay.com

A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis

According to a story from EurekAlert!, a collaborative study headed by researchers from Yale University has furthered the understanding of the mechanisms and progression of fibrosis (scarring) in patients with…

Continue Reading A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
source: pixabay.com

Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status

According to a publication from Scleroderma News, the American Food and Drug Administration (FDA) recently granted Breakthrough Therapy status to Ofev (generic name nintedanib), as a treatment for progressive fibrosing…

Continue Reading Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation
Pexels / Pixabay

A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation

According to a story from Financial Buzz, the biotherapeutics company Bellerophon Therapeutics Inc. has recently announced that it has earned Orphan Drug designation from the US Food and Drug Administration…

Continue Reading A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation
Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
TeroVesalainen / Pixabay

Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease

According to a story from finanzen.at, the drug nintedanib (marketed as Ofev) has officially been approved by the US Food and Drug Administration (FDA) as a treatment for interstitial lung…

Continue Reading Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
This Idiopathic Pulmonary Fibrosis Clinic is Improving Patient Quality of Life
truthseeker08 / Pixabay

This Idiopathic Pulmonary Fibrosis Clinic is Improving Patient Quality of Life

According to a story from Medical Xpress, the Alberta Health Services' Kaye Edmonton Interstitial Lung Disease Clinic is taking a more patient-centered approach to palliative care for patients with idiopathic…

Continue Reading This Idiopathic Pulmonary Fibrosis Clinic is Improving Patient Quality of Life
Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins
source: pixabay.com

Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins

According to a story from BioSpace, the biopharmaceutical company Altavant Sciences has recently announced that the first patient has been dosed in a phase 2a proof of concept trial. This…

Continue Reading Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins